Genetic variations in inflammatory response genes and their association with the risk of prostate cancer

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Cui, Xin ^a   Yan, Hao ^a   Ou, Tong Wen ^a   Jia, Chun Song ^a   Wang, Qi ^a   Xu, Jian Jun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; I KAPPA B; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NFKB1 PROTEIN, HUMAN; NFKBIA PROTEIN, HUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PTGS1 PROTEIN, HUMAN; PTGS2 PROTEIN, HUMAN;

GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HUMAN; MALE; PATHOLOGY; PROMOTER REGION; PROSTATE TUMOR; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; I-KAPPA B PROTEINS; MALE; NF-KAPPA B P50 SUBUNIT; NF-KAPPAB INHIBITOR ALPHA; POLYMORPHISM, SINGLE NUCLEOTIDE; PPAR GAMMA; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84954168105     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/674039     Document Type: Article

References (30)

1. J. Ferlay, I. Soerjomataram, M. Ervik, et al., GLOBOCAN 2012 v1. 0, Cancer Incidence and Mortality Worldwide: IARC Cancer-Base No. 11, International Agency for Research on Cancer, Lyon, France, 2013, http://globocan.iarc.fr.
2. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, "Global cancer statistics, 2002, " Ca: A Cancer Journal for Clinicians, vol. 55, no. 2, pp. 74-108, 2005.
3. L. Zhang, S. Wu, L.-R. Guo, and X.-J. Zhao, "Diagnostic strategies and the incidence of prostate cancer: reasons for the low reported incidence of prostate cancer in China, " Asian Journal of Andrology, vol. 11, no. 1, pp. 9-13, 2009.
4. P. D. Baade, D. R. Youlden, S. M. Cramb, J. Dunn, and R. A. Gardiner, "Epidemiology of prostate cancer in the Asia-Pacific region, " Prostate International, vol. 1, no. 2, pp. 47-58, 2013.
5. M. F. Leitzmann and S. Rohrmann, "Risk factors for the onset of prostatic cancer: age, location, and behavioral correlates, " Clinical Epidemiology, vol. 4, no. 1, pp. 1-11, 2012.
6. O. N. Kryvenko, M. Jankowski, D. A. Chitale, et al., "Inflammation and preneoplastic lesions in benign prostate as risk factors for prostate cancer, " Modern Pathology, vol. 25, no. 7, pp. 1023-1032, 2012.
7. M. M. Shen and C. Abate-Shen, "Molecular genetics of prostate cancer: new prospects for old challenges, " Genes and Development, vol. 24, no. 18, pp. 1967-2000, 2010.
8. A. M. De Marzo, E. A. Platz, S. Sutcliffe, et al., "Inflammation in prostate carcinogenesis, " Nature Reviews Cancer, vol. 7, no. 4, pp. 256-269, 2007.
9. M. J. Alvarez-Cubero, M. Saiz, L. J. Martinez-Gonzalez, J. C. Alvarez, J. A. Lorente, and J. M. Cozar, "Genetic analysis of the principal genes related to prostate cancer: a review, " Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 8, pp. 1419-1429, 2013.
10. S. C. Tan, M. S. M. Suzairi, A. A. A. Aizat, et al., "Gender-specific association of NFKBIA promoter polymorphisms with the risk of sporadic colorectal cancer, " Medical Oncology, vol. 30, no. 4, article 693, 2013.
11. X. Li, S.-J. Wang, S. C. Tan, et al., "The A55T and K153R polymorphisms ofMSTN gene are associated with the strength training-induced muscle hypertrophy among Han Chinese men, " Journal of Sports Sciences, vol. 32, no. 9, pp. 883-891, 2014.
12. M. S. Mohd Suzairi, S. C. Tan, A. A. Ahmad Aizat, et al., "The functional-94 insertion/deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer, " Cancer Epidemiology, vol. 37, no. 5, pp. 634-638, 2013.
13. T. I. Kopp, S. Friis, J. Christensen, A. Tjønneland, and U. Vogel, "Polymorphisms in genes related to inflammation, NSAID use, and the risk of prostate cancer among Danish men, " Cancer Genetics, vol. 206, no. 7-8, pp. 266-278, 2013.
14. R. Kazma, J. A. Mefford, I. Cheng, et al., "Association of the innate immunity and inflammation pathway with advanced prostate cancer risk, " PLoS ONE, vol. 7, no. 12, Article IDe51680, 2012.
15. M. Ianni, E. Porcellini, I. Carbone, et al., "Genetic factors regulating inflammation and DNA methylation associated with prostate cancer, " Prostate Cancer and Prostatic Diseases, vol. 16, no. 1, pp. 56-60, 2013.
16. E. M. Kwon, C. A. Salinas, S. Kolb, et al., "Genetic polymorphisms in inflammation pathway genes and prostate cancer risk, " Cancer Epidemiology, Biomarkers&Prevention, vol. 20, no. 5, pp. 923-933, 2011.
17. H. Martin, "Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components, " Mutation Research, vol. 690, no. 1-2, pp. 57-63, 2010.
18. S. S. Deeb, L. Fajas, M. Nemoto, et al., "A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower bodymass index and improved insulinsensitivity, " Nature Genetics, vol. 20, no. 3, pp. 284-287, 1998.
19. D. Paltoo, K. Woodson, P. Taylor, D. Albanes, J. Virtamo, and J. Tangrea, "Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) gene and risk of prostate cancer among men in a large cancer prevention study, " Cancer Letters, vol. 191, no. 1, pp. 67-74, 2003.
20. J. M. Zmuda, F. Modugno, J. L. Weissfeld, et al., "Peroxisome proliferator-activated receptor-γ polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction, " Oncology, vol. 70, no. 3, pp. 185-189, 2006.
21. A. S. Karban, T. Okazaki, C. I. M. Panhuysen, et al., "Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis, " Human Molecular Genetics, vol. 13, no. 1, pp. 35-45, 2004.
22. P. Zhang, Q. Wei, X. Li, et al., "A functional insertion/deletion polymorphism in the promoter region of the NFKB1 gene increases susceptibility for prostate cancer, " CancerGenetics and Cytogenetics, vol. 191, no. 2, pp. 73-77, 2009.
23. C.-W. Cheng, J.-L. Su, C.-W. Lin, et al., "Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features, " PLoS ONE, vol. 8, no. 2, Article IDe56130, 2013.
24. C.-W. Lin, Y.-S. Hsieh, C.-H. Hsin, et al., "Effects of NFKB1 andNFKBIA gene polymorphisms on susceptibility to environmental factors and the clinicopathologic development of oral cancer, " PLoS ONE, vol. 7, no. 4, Article ID e35078, 2012.
25. M. Umar, R. Upadhyay, S. Kumar, U. C. Ghoshal, and B. Mittal, "Association of common polymorphisms in TNFA, NFkB1 and NFKBIA with risk and prognosis of esophageal squamous cell carcinoma, " PLoS ONE, vol. 8, no. 12, Article IDe81999, 2013.
26. J. Shi, N. L. A. Misso, D. L. Duffy, et al., "Cyclooxygenase-1 gene polymorphisms in patients with different asthma phenotypes and atopy, " European Respiratory Journal, vol. 26, no. 2, pp. 249-256, 2005.
27. H. S. de Vries, R. H. M. te Morsche, M. G. H. van Oijen, I. D. Nagtegaal, W. H. M. Peters, and D. J. de Jong, "The functional 765 → polymorphism of the COX-2 gene may reduce the risk of developing crohns disease, " PLoS ONE, vol. 5, no. 11, Article ID e15011, 2010.
28. S. Sugie, H. Tsukino, S. Mukai, et al., "Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men, " Tumor Biology, vol. 35, no. 3, pp. 2717-2721, 2014.
29. H.-C. Wu, C.-H. Chang, H.-L. Ke, et al., "Association of cyclooxygenase 2 polymorphic genotypes with prostate cancer in Taiwan, " Anticancer Research, vol. 31, no. 1, pp. 221-225, 2011.
30. I. Cheng, X. Liu, S. J. Plummer, L. M. Krumroy, G. Casey, and J. S. Witte, "COX2 genetic variation, NSAIDs, and advanced prostate cancer risk, " British Journal of Cancer, vol. 97, no. 4, pp. 557-561, 2007.